Endo International PLC (NASDAQ:ENDP) issued an update on its FY16 earnings guidance on Friday morning. The company provided EPS guidance of $4.50-4.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.56. The company issued revenue guidance of $3.87-4.03 billion, compared to the consensus revenue estimate of $3.93 billion.Endo International PLC also updated its Q3 guidance to $0.77-0.82 EPS.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 23.39 on Monday. Endo International PLC has a 1-year low of $12.56 and a 1-year high of $72.85. The company’s market cap is $5.21 billion. The company has a 50 day moving average of $21.27 and a 200 day moving average of $21.85.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.12. The firm had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The business’s revenue was up 25.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.08 earnings per share. Equities analysts expect that Endo International PLC will post $4.56 earnings per share for the current fiscal year.
A number of brokerages have weighed in on ENDP. Leerink Swann reissued a market perform rating on shares of Endo International PLC in a research report on Friday. Mizuho reissued a buy rating and set a $29.00 price target on shares of Endo International PLC in a research report on Monday, September 19th. Citigroup Inc. lowered their price target on Endo International PLC from $40.00 to $25.00 and set a buy rating on the stock in a research report on Friday, September 16th. Morgan Stanley set a $16.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Thursday, September 8th. Finally, Vetr raised Endo International PLC from a hold rating to a buy rating and set a $21.95 price target on the stock in a research report on Thursday, August 25th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $39.32.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Advantus Capital Management Inc boosted its position in shares of Endo International PLC by 2.4% in the second quarter. Advantus Capital Management Inc now owns 19,932 shares of the company’s stock worth $311,000 after buying an additional 461 shares during the last quarter. Globeflex Capital L P bought a new stake in Endo International PLC during the second quarter worth $349,000. Panagora Asset Management Inc. increased its stake in Endo International PLC by 29.9% in the second quarter. Panagora Asset Management Inc. now owns 34,828 shares of the company’s stock worth $543,000 after buying an additional 8,019 shares during the last quarter. Sentry Investment Management LLC increased its stake in Endo International PLC by 191.5% in the second quarter. Sentry Investment Management LLC now owns 46,925 shares of the company’s stock worth $732,000 after buying an additional 30,826 shares during the last quarter. Finally, Tredje AP fonden increased its stake in Endo International PLC by 123.3% in the second quarter. Tredje AP fonden now owns 57,835 shares of the company’s stock worth $902,000 after buying an additional 31,935 shares during the last quarter. Institutional investors own 96.64% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.